Download MendeleyDiscovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Wu, Y., Zhou, Q., Zhang, T., Li, Z., Chen, Y.P., Zhang, P., Yu, Y.F., Geng, H., Tian, Y.J., Zhang, C., Wang, Y., Chen, J.W., Chen, Y., Luo, H.B.(2019) J Med Chem 62: 4218-4224
- PubMed: 30916555
- DOI: https://doi.org/10.1021/acs.jmedchem.8b01041
- Primary Citation of Related Structures:
6A3N - PubMed Abstract:
To identify phosphodiesterase-9 (PDE9) as a novel target for the treatment of vascular dementia (VaD), a series of pyrazolopyrimidinone analogues were discovered based on a hit 1. Hit-to-lead optimization resulted in a potent inhibitor 2 with excellent selectivity and physicochemical properties to enable in vivo studies. Oral administration of 2 (5.0 mg/kg) caused notable therapeutic effects in the VaD mouse model, providing a promising lead or chemical probe for investigating the biological functions of PDE9 inhibition.
Organizational Affiliation:
School of Pharmaceutical Sciences , Sun Yat-sen University , Guangzhou 510006 , P. R. China.
